Climb Bio (CLYM) Earnings Analysis

Climb Bio (CLYM) has no confirmed upcoming earnings date. Last quarter (2026-05-07) it beat with EPS -0.2 USD vs -0.26 USD est (+23.1%). It has beaten estimates in 1/3 recent quarters (33%). Trailing P/E -16.13.

Last updated 2026-07-23 · Source: FMP fundamentals + earnings calendar (company filings); consensus from sell-side analyst grades

When does CLYM next report earnings?

No confirmed upcoming earnings date is currently scheduled for CLYM. This page updates as the calendar is published.

CLYM earnings history — beats and misses

Quarter (report date)EPS actualEPS est.SurpriseResult
2026-05-07-0.2 USD-0.26 USD+23.1%Beat
2026-03-05-0.26 USD-0.2 USD-30%Miss
2025-11-06-0.19 USD-0.16 USD-18.8%Miss
2024-08-14-1.81 USDn/an/an/a

Beat rate: 1/3 (33%) over reported quarters with consensus data.

CLYM valuation and analyst view

Trailing P/E-16.13
Trailing EPS-0.77399 USD
Price / book5.79
Dividend yield0.00%
Market cap0.85B
Analyst consensusBuy (5 buy / 0 hold / 0 sell)
Avg price target22.5 USD

Related research pages

Frequently asked questions

When is Climb Bio (CLYM)'s next earnings date?

No confirmed upcoming earnings date is currently scheduled for CLYM. This page updates as the calendar is published.

Did CLYM beat earnings last quarter?

In its 2026-05-07 report, CLYM posted EPS of -0.2 USD versus a -0.26 USD estimate — a beat of 23.1%.

What is CLYM's earnings track record?

Over the last 3 reported quarters with consensus data, CLYM beat estimates 1 times (33%).

What is CLYM's current P/E ratio and EPS?

CLYM trades at a trailing P/E of -16.13 on trailing EPS of -0.7739932520139006 USD.

What do analysts rate CLYM?

Analyst consensus is "Buy" across 5 ratings (0 strong buy, 5 buy, 0 hold, 0 sell, 0 strong sell). Average 12-month price target: 22.5 USD.